Business
WILLOW BIOSCIENCES REPORTS SECOND QUARTER 2022 RESULTS
WILLOW BIOSCIENCES REPORTS SECOND QUARTER 2022 RESULTS Canada NewsWire ...
About this update from Atlas Energy Corp.
[{"type":"text","content":"\n \n \n \n WILLOW BIOSCIENCES REPORTS SECOND QUARTER 2022 RESULTS\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n \n CALGARY, AB\n \n AND\n \n MOUNTAIN VIEW, CA\n \n \n ,\n \n \n Aug. 15, 2022\n \n \n /CNW/ - Willow Biosciences Inc. (\"\n \n Willow\n \n \" or the \"\n \n Company\n \n \") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients, has released its financial and operating results for the three months ended\n \n June 30, 2022\n \n , reporting significant progress to its operational platform, leadership and strong liquidity.\n \n \n \n \n \n \n \n \n \n \"The second quarter saw us take the next step in the evolution of our product portfolio with a new partnered pharmaceutical project\", said Dr. Peter Seufer-Wasserthal, Willow's Interim President and Chief Executive Officer. \"Over the last three and a half years we have built out a fully integrated team that covers the entire production spectrum from the lab to commercialization. We are in a strong position to continue product development of our FutureGrown™ CBG and add new partnerships at this time and believe that the company is set up today to be a leader in the coming bio-revolution of tomorrow.\"\n \n \n Willow's unaudited consolidated interim financial statements and related management's discussion and analysis for the quarter ended\n \n June 30, 2022\n \n are available on SEDAR at\n \n www.sedar.com\n \n .\n \n \n \n Highlights for the Quarter\n \n \n \n \n On\n \n May 11, 2022\n \n , Willow announced that it had successfully completed the initial toxicological assessment for Generally Recognized as Safe (\"\n \n GRAS\n \n \") for its FutureGrown™ cannabigerol (\"\n \n CBG\n \n \") product in\n \n the United States\n \n . An important milestone for biosynthetically produced cannabinoids, Willow has successfully completed the Stage 1 toxicological assessment of its FutureGrown™ CBG product for oral product appl...